Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

65°
- Benton, AR (72018)
  Today
  
  Cloudy with showers. Thunder possible. High 73F. Winds SSE at 5 to 10 mph. Chance of rain 60%..
  
  Tonight
  
  Cloudy with periods of rain. Thunder possible. Low 64F. Winds light and variable. Chance of rain 90%.
  
  Updated: November 20, 2025 @ 12:11 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

919.07 +4.48 (+0.49%)

Streaming Delayed Price Updated: 1:24 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

November 18, 2025

Via Benzinga

Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules ↗

November 14, 2025

Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow.

Via Chartmill

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

November 05, 2025

Via Benzinga

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

How Do Investors Really Feel About argenx SE? ↗

October 13, 2025

Via Benzinga

12 Analysts Have This To Say About argenx ↗

September 18, 2025

Via Benzinga

Is argenx Gaining or Losing Market Support? ↗

September 08, 2025

Via Benzinga

ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗

October 24, 2025

Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.

Via Chartmill

If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today ↗

October 22, 2025

Via Benzinga

Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks ↗

October 22, 2025

Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.

Via The Motley Fool

Topics Workforce

Assessing argenx: Insights From 12 Financial Analysts ↗

October 13, 2025

Via Benzinga

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗

October 13, 2025

Via Benzinga

Assessing argenx: Insights From 11 Financial Analysts ↗

August 25, 2025

Via Benzinga

ARGENX SE - ADR (NASDAQ:ARGX) Matches a Proven Growth Stock Strategy ↗

October 03, 2025

ARGENX stock matches a proven growth strategy, showing explosive earnings revisions, 731% EPS growth, and strong revenue momentum.

Via Chartmill

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

September 29, 2025

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average annual return of 22.36%. Currently, argenx has a market capitalization of...

Via Benzinga

Price Over Earnings Overview: argenx ↗

September 26, 2025

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.08%, but in the past year, went up...

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Via MarketMinute

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

September 10, 2025

Via Benzinga

argenx SE - ADR (NASDAQ:ARGX) Fits Louis Navellier's 'Little Book' Growth Strategy ↗

September 10, 2025

Discover argenx SE (ARGX), a top growth stock meeting Louis Navellier's strict criteria with surging earnings, 97% revenue growth, and strong profitability.

Via Chartmill

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

3 Healthcare Pathbreakers With Long-Term Tailwinds ↗

September 01, 2025

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

Via MarketBeat

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

August 27, 2025

Via Benzinga

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win ↗

August 26, 2025

Argenx advances Vyvgart with strong trial data in seronegative gMG, driving growth projections and reinforcing its leadership in IgG-driven diseases.

Via Benzinga

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗

August 26, 2025

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.

Via Benzinga

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded ↗

August 26, 2025

Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday.

Via Investor's Business Daily

Topics ETFs

Argenx Tops Buy Point On Bullish Study, 850 Price Target ↗

August 25, 2025

Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart. ARGX stock jumped as RBC initiated coverage.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

argenx SE - American Depositary Shares (NQ:ARGX)

Headline News about argenx SE - American Depositary Shares

Sections

Services

Follow Us